Bristol Myers Squibb (Celgene) Deal History & Licensing Activity
Bristol Myers Squibb (Celgene) is a life sciences. Over the past three years, Bristol Myers Squibb (Celgene) has been involved in 2 licensing and acquisition transactions, with a primary focus on Bispecific Antibodies (2 deals). The company currently has 10 active clinical trials, primarily in Hematological Malignancies.
Deals (12mo)
1
Active Trials
10
Top Modality
Bispecific Antibodies
Focus Area
Hematological Malignancies
Bristol Myers Squibb (Celgene) Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Bristol Myers Squibb (Celgene) in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| BNT327 | Bristol Myers Squibb | Bispecific Antibodies | Unknown | co development | Jun 2025 |
Bristol Myers Squibb (Celgene) Pipeline Focus
Therapeutic areas and modalities where Bristol Myers Squibb (Celgene) is most active based on deal history and clinical trial data.
Therapeutic Areas
Bristol Myers Squibb (Celgene) Clinical Pipeline
Bristol Myers Squibb (Celgene) has 10 active clinical trials across 4 development phases.
2
Unknown
3
Phase 1
2
Phase 2
3
Phase 3
See How Your Asset Matches Bristol Myers Squibb (Celgene)'s Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Hematological Malignancies assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Women's Health Deal Benchmarks
Market sizing, deal terms, and competitive landscape for women's health
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Vaccines Benchmarks
Upfront, milestone, and royalty benchmarks for vaccines deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Bristol Myers Squibb (Celgene) Licensing & Deal Activity
Bristol Myers Squibb (Celgene) is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Bristol Myers Squibb (Celgene) ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Bristol Myers Squibb (Celgene) include Hematological Malignancies (5 deals and trials), Women's Health (2 deals and trials), Autoimmune (2 deals and trials), and Solid Tumors (2 deals and trials). In terms of modality, Bristol Myers Squibb (Celgene) has shown particular interest in bispecific antibodies, vaccines.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Bristol Myers Squibb (Celgene) and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Bristol Myers Squibb (Celgene)'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.